- Home
- HRTX vs GOSS Comparison
HRTX vs GOSS Comparison
Compare HRTX & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HRTX | GOSS |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.2M | 70.8M |
| IPO Year | 2007 | 2018 |
Fundamental Metrics
Financial Performance| Metric | HRTX | GOSS |
|---|---|---|
| Price | $0.36 | $8.77 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 8 |
| Target Price | N/A | ★ $95.40 |
| AVG Volume (30 Days) | ★ 2.4M | 291.9K |
| Earning Date | 11-03-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $154,904,000.00 | $48,471,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 7.36 | N/A |
| 52 Week Low | $0.26 | $0.11 |
| 52 Week High | $1.58 | $12.52 |
Technical Indicators
Market Signals| Indicator | HRTX | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 51.30 | 50.74 |
| Support Level | $0.29 | $0.18 |
| Resistance Level | $0.46 | $12.49 |
| Average True Range (ATR) | 0.04 | 0.77 |
| MACD | 0.00 | -0.60 |
| Stochastic Oscillator | 52.02 | 6.83 |
Price Performance
Historical ComparisonAbout HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).